BackgroundHigh expression of the RNA-binding motif protein 3 (RBM3) has previously been described as a favorable clinicopathological factor in several cancers, including ovarian cancer, colorectal cancer, prostate cancer, and breast cancer. The aim of this study was to examine the prognostic implications of RBM3 expression in gastric cancer.Material/MethodsImmunohistochemical analysis of RBM3 expression from 123 patients showed that upregulated RBM3 was mainly found in intestinal-type (n=78, case=59) cancer compared to diffuse-type (n=15, case=8) and mixed-type (n=30, case=17). There were no significant differences in RBM3 expression in subgroups of clinicopathological parameters. RBM3 expression was strongly associated with p53 but not with Ki-67. Cox univariate analysis revealed that high RBM3 expression was closely associated with prolonged overall survival time (HR 0.504, 95% CI: 0.300–0.845, P=0.009). Multivariate analysis remained supporting these associations when adjusted for age, sex, tumor size, differentiation grade, TNM stage, lymphatic invasion, and Ki-67 and p53 expression (HR 0.541, 95% CI: 0.308–0.952, P=0.033), where Lauren grade was not included. Lauren grade was the only factor with independent prognostic significance in a model adjusted for all factors. These results were confirmed by Kaplan-Meier analysis.ResultsTherefore, together with the upregulated RBM3 expression observed in intestinal-type of Lauren grade, we suggest that upregulation of RBM3 is partially responsible for the favorable overall survival in cases with intestinal Lauren grade, which is demonstrated by the box diagram and Kaplan-Meier analysis. Our results showed that high RBM3 expression in gastric cancer is mainly found in intestinal-type of Lauren grade and is associated with longer overall survival time.ConclusionWe found that RBM3 is a potential biomarker of good prognosis and deserves further validation.

No abstract

Buckwheat polysaccharide fractions (BPFs) isolated from seeds of Fagopyrum esculentum have shown extensive immunomodulatory activities including activation of immune system. In this study, the immuno-modulation effects of BPFs on microphages were investigated. The obtained results show that BPFs can activate microphages as indicated by significant increases in the activity of inducible nitric oxide synthase (12.6 ± 1.30 U/mg prot), nuclear factor-kappa B (NF-κB) protein levels, and secretion of nitric oxide (NO) (21.5 ± 1.20 μmol/ml) and tumor necrosis factor-alpha (TNF-α) (71.2 ± 18.20 pg/ml). Moreover, blocking toll-like receptor 4 (TLR4)/NF-κB pathway using a specific antibody to TLR4 or inhibitor of NF-κB led to the significant inhibitory immuno-modulation effect on microphages as indicated by the decrease in the secretion level of NO and TNF-α. It is demonstrated that BPFs can activate microphages and TLR4/NF-κB pathway is involved in the induction of NO and TNF-α in macrophages by BPFs.